Book an appointment with Dr.Ali Chamsedine

Languages

French / Arabic / English

Book an appointment

Qualifications

 Medical Degree (MD)

·French State Doctorate in Medicine – University of Rouen, France (2012)

·MD thesis awarded with highest academic distinction with committee commendation

French Board Certifications:

· Medical Oncology

· Clinical Hematology

Residency & Fellowship in Medical Oncology and Clinical Hematology (France)

·Rouen University Hospital & Henri Becquerel Cancer Center, France (2008–2012)

·Multidisciplinary training across Oncology, Clinical Hematology and Bone Marrow Transplantation / Hematopoietic Stem Cell Transplantation, Internal Medicine

Postdoctoral Fellowship in Leukemia

·MD Anderson Cancer Center, Houston, Texas, USA (2015–2016)

·Focus: Therapeutic resistance and biomarker development in the MDS and AML setting.

Former Senior Consultant Medical Oncologist at Gustave Roussy Cancer Center (France)

·Department of Clinical Hematology and Bone Marrow Transplantation (2013–2015)

·Department of Cancer Medicine (2016–2022)

PhD in Public Health and Molecular Oncology

·University of Paris-Saclay, France (2021)

·PhD thesis awarded summa cum laude with committee commendation

 MSc in Clinical Research

·University of Paris VI (Pierre and Marie Curie), France (2017)

· Major: Methodology in clinical trials and biostatistics

 University Diplomas (DU)

·Clinical Oncology – University of Paris XI (2013)

·Allogeneic Hematopoietic Stem Cell Transplantation – University of Paris VI (2014)

·Personalized Medicine & Pharmacogenomics – University of Paris VI (2017)

·Immuno-Oncology – University of Paris-Sud / Paris XI (2019)

 Professional Licensure

·French Medical Council (RPPS No. 10100558575)

·Dubai Health Authority – Consultant Medical Oncology (ID: 78019105)

Dr.Ali Chamsedine

Consultant Medical Oncologist and Clinical Hematologist

Dr. Ali Chamseddine is a Consultant Medical Oncologist and Clinical Hematologist with over 15 years of experience in comprehensive cancer care. He is French Board-certified in both Medical Oncology and Clinical Hematology. His training in both France and the United States equips him with international expertise that enhances his practice. He also holds a PhD in Public Health and Molecular Oncology from the prestigious University of Paris-Saclay, where he was awarded the highest honors, summa cum laude. His doctoral research developed novel statistical methodologies for assessing treatment efficacy in advanced gastric cancer, contributing to clinical trial design and evidence generation.

Dr. Chamseddine completed his residency and fellowship in Oncology and Hematology at the University of Rouen and the Henri-Becquerel Cancer Center. He later worked as Senior Assistant Physician at Gustave Roussy Cancer Center in Villejuif, France, Europe’s leading cancer institute, before pursuing a postdoctoral fellowship in leukemia at MD Anderson Cancer Center in Houston, USA, recognized as the world’s foremost cancer center. Upon returning to France, he held senior consultant roles at Gustave Roussy Cancer Center, where he led the Jules Verne Unit within the International Department of Oncology, as well as at the Ambroise Paré-Hartmann Group and Cochin Hospital (AP-HP, Paris), focusing on digestive and solid tumor oncology.

In the UAE, Dr. Chamseddine was the founding Head of Oncology at Dr. Sulaiman Al Habib Hospital in Dubai, where he established the department and introduced advanced oncology services.

He is a recognized expert in precision oncology, with strong academic credentials in immuno-oncology, pharmacogenomics, clinical research, and personalized medicine. Dr. Chamseddine has published over 45 peer-reviewed publications, including a letter in The New England Journal of Medicine, which highlights his contributions to significant clinical discussions in oncology.

At Al Zahra Hospital Dubai, Dr. Chamseddine treats the full spectrum of solid tumors and hematologic malignancies, with a particular emphasis on gastrointestinal, breast, lung, genitourinary, and gynecologic cancers, as well as soft tissue sarcomas, lymphomas, and multiple myeloma. He routinely integrates molecular profiling, liquid biopsy, and pharmacogenomic-guided strategies into highly personalized treatment plans. At Al Zahra Hospital Dubai, Dr. Chamseddine collaborates with esteemed colleagues in the multidisciplinary Cancer Center, delivering state-of-the-art, compassionate and individualized cancer care.

Fluent in French, English, and Arabic, Dr. Chamseddine provides care for both local and international patients. He is an active member of several international professional bodies, including ESMO (European Society for Medical Oncology), ASCO (American Society of Clinical Oncology), ASH (American Society of Hematology), and EHA (European Hematology Association), and sits on the scientific committee of the Francophone Federation of Digestive Oncology (FFCD). He is also the founder and general secretary of the French Lebanese Oncology Meeting (FLOM).

Specializations

Solid Tumors:

  • Gastrointestinal Cancers: Esophageal, Gastric (Stomach), Colorectal, Pancreatic, Liver (HCC), Bile Duct (Intra- and Extrahepatic Cholangiocarcinoma), Gallbladder, Neuroendocrine Tumors (NETs), and Carcinoid Tumors
  • Breast Cancer: Hormone receptor–positive, HER2-positive, and triple-negative subtypes
  • Gynecologic Cancers: Ovarian, Cervical, Endometrial (Uterine), Vaginal, and Vulvar Cancers
  • Genitourinary Cancers: Prostate, Bladder, Kidney (RCC & non-RCC), Testicular, and Penile Cancers
  • Lung and Thoracic Cancers: Non-small cell, Small cell lung cancer, Mesothelioma and Thymomas
  • Central Nervous System (CNS) Tumors: Primary brain tumors and metastatic brain disease
  • Soft-Tissue and Bone Sarcomas

Hematologic Malignancies:

  • Lymphomas: Hodgkin and Non-Hodgkin (including Follicular, DLBCL, Marginal Zone, T-cell lymphomas)
  • Multiple Myeloma and Plasma Cell Disorders
  • Myeloproliferative Neoplasms

Advanced Therapeutic Expertise:

  • Chemotherapy (IV, Oral and Intrathecal) administration and related toxicity management
  • Immunotherapy (Immune Checkpoint Inhibitors) administration and related toxicity management
  • Targeted therapies, Tyrosine Kinase Inhibitors (TKIs) and monoclonal antibodies
  • Endocrine therapy for breast and prostate cancers
  • Bone marrow biopsy and aspiration
  • Second opinions for complex/rare cancers

Academic Contributions & Memberships

  • Over 45 peer-reviewed publications, including in The New England Journal of Medicine
  • Research focused on molecular profiling, biomarker discovery, and precision cancer medicine
  • Scientific Committee Member – Francophone Federation of Digestive Oncology (FFCD)
  • Founder and General Secretary – French Lebanese Oncology Meeting (FLOM)
  • Member of ESMO (European Society for Medical Oncology)
  • Member of ASCO (American Society of Clinical Oncology)
  • Member of ASH (American Society of Hematology)
  • Member EHA (European Hematology Association)

Academic Contributions & Memberships

  • Over 45 peer-reviewed publications, including in The New England Journal of Medicine
  • Research focused on molecular profiling, biomarker discovery, and precision cancer medicine
  • Scientific Committee Member – Francophone Federation of Digestive Oncology (FFCD)
  • Founder and General Secretary – French Lebanese Oncology Meeting (FLOM)
  • Member of ESMO (European Society for Medical Oncology)
  • Member of ASCO (American Society of Clinical Oncology)
  • Member of ASH (American Society of Hematology)
  • Member EHA (European Hematology Association)

Precision Oncology & Personalized Treatment Planning through:

  • Molecular profiling and biomarker-guided treatment
  • Comprehensive genomic testing (NGS, ctDNA, MSI-H, TMB, BRCA/HRD)
  • Pharmacogenomics
  • Academic collaboration in translational and investigator-initiated research
  • Immunotherapy and checkpoint inhibitors
  • Chemotherapy and endocrine therapy
  • Targeted therapies, TKIs, monoclonal antibodies
  • Bone marrow biopsy and diagnostic procedures
  • Multidisciplinary tumor board participation
  • Integration of palliative care and survivorship programs

Supportive & Survivorship Care:

  • Management of cancer-related symptoms (e.g., pain, nausea, fatigue, cachexia, anemia)
  • Oncologic emergencies (e.g., spinal cord compression, tumor lysis syndrome, febrile neutropenia)
  • Palliative care integration and end-of-life planning
  • Fertility preservation counseling for cancer patients
  • Long-term survivorship and secondary cancer prevention
  • Cancer screening and preventive oncology (especially in high-risk populations)
  • Patient education and multidisciplinary shared decision-making

 

Book an appointment

Dr.Ali Chamsedine

Consultant Medical Oncologist and Clinical Hematologist

Dr. Ali Chamseddine is a Consultant Medical Oncologist and Clinical Hematologist with over 15 years of experience in comprehensive cancer care. He is French Board-certified in both Medical Oncology and Clinical Hematology. His training in both France and the United States equips him with international expertise that enhances his practice. He also holds a PhD in Public Health and Molecular Oncology from the prestigious University of Paris-Saclay, where he was awarded the highest honors, summa cum laude. His doctoral research developed novel statistical methodologies for assessing treatment efficacy in advanced gastric cancer, contributing to clinical trial design and evidence generation.

Dr. Chamseddine completed his residency and fellowship in Oncology and Hematology at the University of Rouen and the Henri-Becquerel Cancer Center. He later worked as Senior Assistant Physician at Gustave Roussy Cancer Center in Villejuif, France, Europe’s leading cancer institute, before pursuing a postdoctoral fellowship in leukemia at MD Anderson Cancer Center in Houston, USA, recognized as the world’s foremost cancer center. Upon returning to France, he held senior consultant roles at Gustave Roussy Cancer Center, where he led the Jules Verne Unit within the International Department of Oncology, as well as at the Ambroise Paré-Hartmann Group and Cochin Hospital (AP-HP, Paris), focusing on digestive and solid tumor oncology.

In the UAE, Dr. Chamseddine was the founding Head of Oncology at Dr. Sulaiman Al Habib Hospital in Dubai, where he established the department and introduced advanced oncology services.

He is a recognized expert in precision oncology, with strong academic credentials in immuno-oncology, pharmacogenomics, clinical research, and personalized medicine. Dr. Chamseddine has published over 45 peer-reviewed publications, including a letter in The New England Journal of Medicine, which highlights his contributions to significant clinical discussions in oncology.

At Al Zahra Hospital Dubai, Dr. Chamseddine treats the full spectrum of solid tumors and hematologic malignancies, with a particular emphasis on gastrointestinal, breast, lung, genitourinary, and gynecologic cancers, as well as soft tissue sarcomas, lymphomas, and multiple myeloma. He routinely integrates molecular profiling, liquid biopsy, and pharmacogenomic-guided strategies into highly personalized treatment plans. At Al Zahra Hospital Dubai, Dr. Chamseddine collaborates with esteemed colleagues in the multidisciplinary Cancer Center, delivering state-of-the-art, compassionate and individualized cancer care.

Fluent in French, English, and Arabic, Dr. Chamseddine provides care for both local and international patients. He is an active member of several international professional bodies, including ESMO (European Society for Medical Oncology), ASCO (American Society of Clinical Oncology), ASH (American Society of Hematology), and EHA (European Hematology Association), and sits on the scientific committee of the Francophone Federation of Digestive Oncology (FFCD). He is also the founder and general secretary of the French Lebanese Oncology Meeting (FLOM).

Languages

French / Arabic / English

Book an appointment

Qualifications

 Medical Degree (MD)

·French State Doctorate in Medicine – University of Rouen, France (2012)

·MD thesis awarded with highest academic distinction with committee commendation

French Board Certifications:

· Medical Oncology

· Clinical Hematology

Residency & Fellowship in Medical Oncology and Clinical Hematology (France)

·Rouen University Hospital & Henri Becquerel Cancer Center, France (2008–2012)

·Multidisciplinary training across Oncology, Clinical Hematology and Bone Marrow Transplantation / Hematopoietic Stem Cell Transplantation, Internal Medicine

Postdoctoral Fellowship in Leukemia

·MD Anderson Cancer Center, Houston, Texas, USA (2015–2016)

·Focus: Therapeutic resistance and biomarker development in the MDS and AML setting.

Former Senior Consultant Medical Oncologist at Gustave Roussy Cancer Center (France)

·Department of Clinical Hematology and Bone Marrow Transplantation (2013–2015)

·Department of Cancer Medicine (2016–2022)

PhD in Public Health and Molecular Oncology

·University of Paris-Saclay, France (2021)

·PhD thesis awarded summa cum laude with committee commendation

 MSc in Clinical Research

·University of Paris VI (Pierre and Marie Curie), France (2017)

· Major: Methodology in clinical trials and biostatistics

 University Diplomas (DU)

·Clinical Oncology – University of Paris XI (2013)

·Allogeneic Hematopoietic Stem Cell Transplantation – University of Paris VI (2014)

·Personalized Medicine & Pharmacogenomics – University of Paris VI (2017)

·Immuno-Oncology – University of Paris-Sud / Paris XI (2019)

 Professional Licensure

·French Medical Council (RPPS No. 10100558575)

·Dubai Health Authority – Consultant Medical Oncology (ID: 78019105)

Specializations

Solid Tumors:

  • Gastrointestinal Cancers: Esophageal, Gastric (Stomach), Colorectal, Pancreatic, Liver (HCC), Bile Duct (Intra- and Extrahepatic Cholangiocarcinoma), Gallbladder, Neuroendocrine Tumors (NETs), and Carcinoid Tumors
  • Breast Cancer: Hormone receptor–positive, HER2-positive, and triple-negative subtypes
  • Gynecologic Cancers: Ovarian, Cervical, Endometrial (Uterine), Vaginal, and Vulvar Cancers
  • Genitourinary Cancers: Prostate, Bladder, Kidney (RCC & non-RCC), Testicular, and Penile Cancers
  • Lung and Thoracic Cancers: Non-small cell, Small cell lung cancer, Mesothelioma and Thymomas
  • Central Nervous System (CNS) Tumors: Primary brain tumors and metastatic brain disease
  • Soft-Tissue and Bone Sarcomas

Hematologic Malignancies:

  • Lymphomas: Hodgkin and Non-Hodgkin (including Follicular, DLBCL, Marginal Zone, T-cell lymphomas)
  • Multiple Myeloma and Plasma Cell Disorders
  • Myeloproliferative Neoplasms

Advanced Therapeutic Expertise:

  • Chemotherapy (IV, Oral and Intrathecal) administration and related toxicity management
  • Immunotherapy (Immune Checkpoint Inhibitors) administration and related toxicity management
  • Targeted therapies, Tyrosine Kinase Inhibitors (TKIs) and monoclonal antibodies
  • Endocrine therapy for breast and prostate cancers
  • Bone marrow biopsy and aspiration
  • Second opinions for complex/rare cancers

Academic Contributions & Memberships

  • Over 45 peer-reviewed publications, including in The New England Journal of Medicine
  • Research focused on molecular profiling, biomarker discovery, and precision cancer medicine
  • Scientific Committee Member – Francophone Federation of Digestive Oncology (FFCD)
  • Founder and General Secretary – French Lebanese Oncology Meeting (FLOM)
  • Member of ESMO (European Society for Medical Oncology)
  • Member of ASCO (American Society of Clinical Oncology)
  • Member of ASH (American Society of Hematology)
  • Member EHA (European Hematology Association)

Academic Contributions & Memberships

  • Over 45 peer-reviewed publications, including in The New England Journal of Medicine
  • Research focused on molecular profiling, biomarker discovery, and precision cancer medicine
  • Scientific Committee Member – Francophone Federation of Digestive Oncology (FFCD)
  • Founder and General Secretary – French Lebanese Oncology Meeting (FLOM)
  • Member of ESMO (European Society for Medical Oncology)
  • Member of ASCO (American Society of Clinical Oncology)
  • Member of ASH (American Society of Hematology)
  • Member EHA (European Hematology Association)

Precision Oncology & Personalized Treatment Planning through:

  • Molecular profiling and biomarker-guided treatment
  • Comprehensive genomic testing (NGS, ctDNA, MSI-H, TMB, BRCA/HRD)
  • Pharmacogenomics
  • Academic collaboration in translational and investigator-initiated research
  • Immunotherapy and checkpoint inhibitors
  • Chemotherapy and endocrine therapy
  • Targeted therapies, TKIs, monoclonal antibodies
  • Bone marrow biopsy and diagnostic procedures
  • Multidisciplinary tumor board participation
  • Integration of palliative care and survivorship programs

Supportive & Survivorship Care:

  • Management of cancer-related symptoms (e.g., pain, nausea, fatigue, cachexia, anemia)
  • Oncologic emergencies (e.g., spinal cord compression, tumor lysis syndrome, febrile neutropenia)
  • Palliative care integration and end-of-life planning
  • Fertility preservation counseling for cancer patients
  • Long-term survivorship and secondary cancer prevention
  • Cancer screening and preventive oncology (especially in high-risk populations)
  • Patient education and multidisciplinary shared decision-making

 

Book an appointment